With increased demand for immunity and nutrition products during the coronavirus lockdown, direct selling major Amway is gearing up for enhanced focus on the category and expecting up to 65 per cent of its total business to come from it going forward, a top company official said.
The company, which is taking a look at its "portfolio in a big way" in India as part of planned global investments, is studying how to readjust the portfolio more towards immunity and nutrition here in the country.
Amway India also expects its business to come back to at least 80-90 per cent of pre-lockdown levels by July.
During the lockdown, a consumer trend has been observed with demand moving towards immunity and nutrition products, Amway India CEO Anshu Budhraja told PTI.
"People are more attuned to consuming for their own self-care...During the lockdown the classic case is that people did not want to go to hospital, otherwise people earlier wanted to go to doctors for true curative (treatment). People have now moved to preventive and they see see value in preventive," he said.
Therefore, he said, "the need for supplementation is leading to the heightened awareness for stronger immunity. I think that is one big mega trend which we see. We have coined the term 'What's IN' and IN stands for immunity and nutrition."
Asked if the company would ramp up production of such immunity and nutrition products, he said, "Good companies always follow consumer demands and consumer needs. If consumer demands and needs towards immunity supporting range goes up, obviously we will support that."
Predicting that this market will grow over a period of time, he said, "It will grow more than the market in beauty (category) in the mid-term at least. We do see a mix change in our portfolio where immunity and nutrition will move up to almost 60-65 per cent of the total business as compared to almost 56 per cent at present."
He further said,"We envisage that these categories will grow at a much faster pace because consumer is evolving and naturally inclined to migrate into those segment."
Reiterating the company's focus on the segment as part of planned global investments, Budhraja said, "We are looking at portfolio in a big way, how we can readjust our portfolio more towards immunity and nutrition. We are looking at multiple things around that."
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
